Philadelphia chromosome-positive acute lymphoblastic leukemia in children: New and emerging treatment options

Expert Review of Hematology

Volumn 3, Issue 6, 2010, Pages 731-742

  Schultz, Kirk R ^a   Prestidge, Tim ^a   Camitta, Bruce ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

acute lymphoblastic leukemia; adolescents; children; hematopoietic cell transplantation; Philadelphia chromosome; tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; CYTOPENIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GROWTH RETARDATION; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH DISEASE; TREATMENT DURATION; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RISK FACTORS; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649505429     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.60     Document Type: Review

References (79)

1. Schultz KR, Pullen DJ, Sather HN et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109(3), 926-935 (2007).
2. Arico M, Valsecchi MG, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342(14), 998-1006 (2000). (Pubitemid 30180646)
3. Sharathkumar A, Saunders EF, Dror Y et al. Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosomepositive acute lymphoblastic leukemia. Bone Marrow Transplant. 33(1), 39-45 (2004).
4. Satwani P, Sather H, Ozkaynak F et al. Allogeneic bone marrow transplantation in first remission for children with ultra-highrisk features of acute lymphoblastic leukemia: A children's oncology group study report. Biol. Blood Marrow Transplant. 13(2), 218-227 (2007).
5. Sharathkumar A, Saunders EF, Dror Y et al. Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosomepositive acute lymphoblastic leukemia. Bone Marrow Transplant. 33(1), 39-45 (2004).
6. Arico M, Schrappe M, Hunger S et al. Clinical outcome of 640 children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. Blood (ASH Annual Meeting Abstracts) 112(11), 568 (2008).
7. Lee S, Kim YJ, Min CK et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 105(9), 3449-3457 (2005).
8. Mizuta S, Sugiura I, Yagasaki F et al. Efficacy of allogeneic hematopoietic stem cell transplantation during first complete remission following imatinib-combined chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 112(11), 462 (2008).
9. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
10. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
11. Deininger MW, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698 (1997).
12. Kasper B, Fruehauf S, Schiedlmeier B et al. Favorable therapeutic index of a p210 (BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother. Pharmacol. 44, 433-438 (1999).
13. Le Coutre P, Mologni L, Cleris L et al. In vivo eradication of human BCR/ ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst. 91, 163-168 (1999).
14. Beran M, Cao X, Estrov Z et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4, 1661-1672 (1998).
15. Druker BJ, Kantarjian H, Sawyers CL et al. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Blood 94, 697a (1999).
16. Champagne MA, Capdeville R, Krailo M et al. Children's Oncology Group Phase 1 study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group Phase 1 study. Blood 104(9), 2655-2660 (2004). Established that there was no maximum tolerated dose for imatinib in children on the basis of a Phase II trial in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
17. Schultz KR, Bowman WP, Aledo A et al. Improved early event-free survival with imatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia: A Children's Oncology Group study. J. Clin. Oncol. 27(31), 5175-5181 (2009). Established that imatinib in combination with an intensive chemotherapy background resulted in a significant improvement in Ph+ ALL in children.
18. Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12), 2788-2801 (2004). Established that imatinib in combination with intensive chemotherapy in adults results in an improved outcome, although not as good as in the pediatric population.
19. Thomas DA, Faderl S, Cortes J et al. Treatment of Philadelphia chromosomepositive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12), 4396-4407 (2004).
20. Schultz KR, Aledo A, Bowman WP et al. Continuous dosing imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with longer term follow up: Updated results of Children's Oncology Group (COG) AALL0031. Presented at: American Society of Pediatric Hematology/Oncology 2010 Meeting. Montreal, Quebec, Canada, 7-10 April 2010. This presentation supported that the early excellent improvement in the early outcomes of the Children's Oncology Group Ph+ ALL trial was durable after longer follow-up.
21. Lee KH, Lee JH, Choi SJ et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia. Leukemia 19(9), 1509-1516 (2005).
22. Yanada M, Takeuchi J, Sugiura I et al. Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A Phase II study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24(3), 460-466 (2006).
23. Wassmann B, Pfeifer H, Goekbuget N et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108(5), 1469-1477 (2006).
24. Chalandon Y, Thomas X, Hayette S et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia. Blood 112, 11 (2008).
25. Delannoy A, Delabesse E, Lhéritier V et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study. Leukemia 20(9), 1526-1532 (2006).
26. Rea D, Legros L, Raffoux E et al. Intergroupe Français des Leucémies Myéloïdes Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20(3), 400-403 (2006).
27. Ottmann OG, Wassmann B, Pfeifer H et al. GMALL Study Group. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 109(10), 2068-2076 (2007).
28. Mullighan CG, Zhang J, Harvey RC et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106(23), 9414-9418 (2009).
29. Carpenter PA, Snyder DS, Flowers ME et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109(7), 2791-2793 (2007).
30. Satwani P, Sather H, Ozkaynak F et al. Allogeneic bone marrow transplantation in first remission for children with ultra-highrisk features of acute lymphoblastic leukemia: A Children's Oncology Group study report. Biol. Blood Marrow Transplant. 13(2), 218-227 (2007).
31. Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27(3), 469-471 (2009) 32 O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5), 401-412 (2009).
32. Tanaka R, Squires MS, Kimura S et al. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 116(12), 2089-2095 (2010).
33. Van Etten RA, Chan WA, Zaleskas VM et al. Switch pocket inhibitors of the ABL tyrosine kinase: Distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I. Blood 112(11), 216-216 (2008).
34. Huang WS, Metcalf CA, Sundaramoorthi R et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4- methylpiperazin-1-yl)methyl]-3- (trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem. 53(12), 4701-4719 (2010).
35. Jones D, Thomas D, Yin CC et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113(5), 985-994 (2008).
36. Chang BH, Willis SG, Stork LC et al. Mutational analysis of BCR-AbI from subjects with relapsed Ph plus ALL treated on the COG protocol AALL0031: A report from the Children's Oncology Group. Blood 114(22), 1033-1034 (2009).
37. White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity imatinib. Blood 108(2), 697-704 (2006).
38. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2), 690-698 (2003).
39. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004).
40. le Coutre P, Tassi E, Varella-Garcia M et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95(5), 1758-1766 (2000).
41. Li S, Li D. Stem cell and kinase activityindependent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J. Cell. Mol. Med. 11(6), 1251-1262 (2007).
42. Jiang X, Forrest D, Nicolini F et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 116(12), 2112-2121 (2010).
43. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010). Provides early data in adults showing that that the minimal residual disease response induced by the secondgeneration tyrosine kinase inhibitor dasatinib is better than imatinib in chronic myeloid leukemia.
44. Saglio G, Kim DW, Issaragrisil S et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010). Provides early data in adults that the minimal residual disease response induced by the second-generation tyrosine kinase inhibitor nilotinib is better than imatinib in chronic myeloid leukemia.
45. Kolb EA, Gorlick R, Houghton PJ et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(6), 1198-1206 (2008). (Pubitemid 351555544)
46. Porkka K, Koskenvesa P, Lundán T et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia. Blood 112(4), 1005-1012 (2008).
47. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354(24), 2531-2541 (2006). (Pubitemid 43882349)
48. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a Phase 2 study. Blood 110(7), 2309-2315 (2007).
49. Ravandi F, O'Brien S, Thomas D et al. First report of Phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12), 2070-2077 (2010).
50. Rousselot P, Cayuela JM, Recher C et al. Dasatinib (Sprycel®) and chemotherapy for first line treatment in elderly patienst with de novo Phildelphia positive ALL: Results of the first 22 patients included in the EWALL-Ph-01 trial (on behalf of the European Working Group in Adult ALL [EWALL]) (abstract). Blood 112, 1004 (2009).
51. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNF-a following TLR stimulation in vitro and in vivo. Exp. Hematol. 37(12), 1435-1444 (2009).
52. Shimokaze T, Mitsui T, Takeda H et al. Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 26(6), 448-453 (2009).
53. Fraser CK, Blake SJ, Diener KR et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37(2), 256-265 (2009).
54. Mustjoki S, Ekblom M, Arstila TP et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23(8), 1398-1405 (2009).
55. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542-2551 (2006). (Pubitemid 43882350)
56. Tojo A, Usuki K, Urabe A et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int. J. Hematol. 89(5), 679-688 (2009).
57. Kang BW, Moon JH, Chae YS, Kim JG, Kim SN, Sohn SK. Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. Acta Haematol. 123(4), 242-247 (2010).
58. Soverini S, Gnani A, Colarossi S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114(10), 2168-2171 (2009).
59. Arico M, Valsecchi MG, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342(14), 998-1006 (2000). (Pubitemid 30180646)
60. Schrappe M, Arico M, Harbott J et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92(8), 2730-2741 (1998). One of the first papers to provide prognostic indicators for Ph+ ALL in children.
61. Pane F, Cimino G, Izzo B et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 19, 628-635 (2005).
62. Yanada M, Takeuchi J, Sugiura I et al. Japan Adult Leukemia Study Group. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 93(2), 287-290 (2008).
63. Carroll AJ, Heerema NA, Devidas M et al. Secondary chromosomal abnormalities appear to be less prognostic for children with Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukemia (ALL) treated with intensified imatinib and chemotherapy: Results of the Children's Oncology Group (COG) study AALL0031. Blood 114(22), 1022-1023 (2009).
64. Suttorp M, Thiede C, Tauer JT et al. Chronic myeloid leukemia in pediatrics - first results from study CML-PAED II. Blood 114(22), 145-145 (2009) (Abstract 342).
65. Riva G, Luppi M, Barozzi P et al. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood 115(8), 1512-1518 (2010).
66. Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 94(8), 1177-1179 (2009).
67. Vandyke K, Dewar AL, Fitter S et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 23(11), 2155-2159 (2009).
68. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int. J. Hematol. 89(2), 251-252 (2009).
69. Goldstone AH, Richards SM, Lazarus HM et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111(4), 1827-1833 (2008).
70. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in The Netherlands. Leukemia 18(12), 2032-2035 (2004).
71. DeAngelo DJ, Silverman LB, Couban S et al. A multicenter Phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia (Abstract). Blood 110, 587 (2007).
72. Huguet F, Leguay T, Raffoux E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J. Clin. Oncol. 27(6), 911-918 (2009).
73. Storring JM, Brandwein J, Gupta V et al. Treatment of adult lymphoblastic leukemia (ALL) with a modified DFCI pediatric regimen - the Princess Margaret experience. Blood 108, 1875 (2006).
74. Ramanujachar R, Richards S, Hann I et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr. Blood Cancer 48(3), 254-261 (2008).
75. Ribera JM, Oriol A, Sanz MA et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J. Clin. Oncol. 26(11), 1843-1849 (2008).
76. de Labarthe A, Rousselot P, Huguet-Rigal F et al.; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 109(4), 1408-1413 (2007).
77. Thomas DA, Kantarjian HM, Cortes J et al. Outcome after frontline therapy with hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) (abstract). Blood 112, 1008 (2008).
78. Bassan R, Rossi G, Pogliani EM et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J. Clin. Oncol. 28(22), 3644-3652 (2010).
79. Foa R, Vitale A, Guarini A et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study (abstract). Blood 112, 305 (2008).